Intuitive Surgical, Inc. (ISRG) Misses Q2 EPS by 14c
Intuitive Surgical, Inc. (NASDAQ: ISRG) reported Q2 EPS of $3.90, $0.14 worse than the analyst estimate of $4.04. Revenue for the quarter came in at $579 million versus the consensus estimate of $594.58 million.
NOTE: Company warned on July 8th
Intuitive Surgical ended the second quarter of 2013 with $3.0 billion in cash, cash equivalents and investments, reflecting a decrease of $89 million during the quarter. $270 million in cash was used to repurchase approximately 546,000 shares of Intuitive Surgical's common stock in the second quarter of 2013 at an average price of $494 per share.
Intuitive Surgical sees full year revenues unchanged to up 7%, which is below Wall Street views of up 14%. The company sees procedures up 15-18%, versus its prior outlook of 20-23%.
Intuitive Surgical also said it received an FDA warning letter after inspection.
For earnings history and earnings-related data on Intuitive Surgical, Inc. (ISRG) click here.
NOTE: Company warned on July 8th
Intuitive Surgical ended the second quarter of 2013 with $3.0 billion in cash, cash equivalents and investments, reflecting a decrease of $89 million during the quarter. $270 million in cash was used to repurchase approximately 546,000 shares of Intuitive Surgical's common stock in the second quarter of 2013 at an average price of $494 per share.
Intuitive Surgical sees full year revenues unchanged to up 7%, which is below Wall Street views of up 14%. The company sees procedures up 15-18%, versus its prior outlook of 20-23%.
Intuitive Surgical also said it received an FDA warning letter after inspection.
For earnings history and earnings-related data on Intuitive Surgical, Inc. (ISRG) click here.